Tamtam Try Tamtam free
Guardant Health logo

Guardant Health account plan

advanced cancer detection technology

At a glance

Guardant Health is a precision oncology company selling blood and tissue cancer tests, with $982.0 million revenue in 2025 and 2,506 employees.

Guardant Health sells blood and tissue tests, real-world data and AI analytics across cancer care: screening (Shield), recurrence monitoring (Guardant Reveal) and therapy selection (Guardant360), plus tests, companion diagnostic development and data services for biopharmaceutical companies. Its customers are oncologists, primary care physicians, cancer centers and health systems, reimbursed by Medicare and commercial payers, and biopharma companies; 96% of 2025 revenue came from the United States. FY2025 revenue was $982.0 million, up 33%, with a net loss of $416.3 million. It had 2,506 employees at December 31, 2025, and labs in Redwood City, Long Island City, San Diego and Palo Alto. It is run by Co-CEOs Helmy Eltoukhy and AmirAli Talasaz.

Business units

Strategic priorities

Scale Shield screening
Grow Shield through the field organization, the Quest collaboration and DTC campaigns; coverage is expected to reach about 100 million people, more than 80% of the eligible U.S. population, entering 2027.
Cut Shield cost per test
Shield cost per test fell from $410 in Q2 to $330 in Q3 2026, with a new automated Palo Alto lab going live in 2027 and a target of $200 by the end of 2028.
Repeat testing in therapy selection
Guardant360 Liquid CDx (FDA-approved in 2026) and the camizestrant CDx approval push toward testing at each therapy decision; ADLT status is expected in the first half of 2027.
Reveal Ultra and MRD
Reveal Ultra launched to biopharma partners with clinical launch before year-end 2026; management calls it the biggest opportunity in the portfolio.
Free cash flow breakeven
The business excluding Screening generates positive free cash flow in 2026, and company-wide free cash flow breakeven is targeted by the end of 2027.
Data and AI platform
The Smart Platform and InfinityAI engine draw on more than 1.5 million patient tests and more than 900,000 epigenetic profiles, with smart apps and a conversational AI decision-support pilot.

Latest results

In Q3 2026 revenue rose 36% to $361.0 million from $265.2 million, with Oncology at $231.3 million (+25%), Screening at $67.6 million (+180%) and Biopharma & Data at $59.0 million (+8%). Non-GAAP gross margin was 67% versus 66%, while the net loss widened to $124.4 million from $92.7 million as legal expenses and sales and marketing rose. Adjusted EBITDA loss narrowed to $37.3 million and free cash flow was $(37.2) million. 2026 revenue guidance was raised to $1.36-$1.37 billion (+38% to 40%), with a free cash flow burn of $205-$220 million. Cash, cash equivalents and restricted cash were $1.1 billion at September 30, 2026.

Investments and deals

MetaSight Diagnostics acquisition
Acquired in December 2025 for $59.0 million upfront plus up to $90.0 million contingent on commercial performance and regulatory approvals.
Shield lab capacity and automation
A higher-throughput, lower-COGS Shield workflow approved and deployed in 2026, and a new automated Palo Alto lab going live in 2027.
Commercial build-out
Sales and marketing rose 36% to $494.7 million in 2025 for the Shield launch, with a field organization of over 400 professionals.
Financing
In 2025, $402.5 million of convertible notes and $257.1 million of equity raised, and $600.0 million of 1.25% 2031 notes exchanged for 2027 notes.
International partner labs
In-country labs with VHIO, Royal Marsden, Policlinico Gemelli and Adicon, and Shield MCD launched in multiple Asian markets.

Challenges and risks

Continued losses
Net loss of $416.3 million in 2025 and an accumulated deficit of $3.4 billion at September 30, 2026.
Reimbursement timing and variability
CMS cannot process Guardant360 liquid CDx claims until January 2027, shifting $10 million to $15 million of payments; payer rate setting and coding changes add variability.
Litigation
The TwinStrand verdict was upheld with a 6% ongoing royalty and $110.2 million held as surety collateral; legal expenses rose $22.6 million in Q3 2026.
Competition
Competitors include Foundation Medicine (Roche), Caris, Tempus AI, NeoGenomics, Exact Sciences, Natera, GRAIL and Freenome.
Cybersecurity incident
Unauthorized access to its electronic ordering portal, where an unauthorized party is believed to have accessed certain patient records; the investigation continues.

What leadership says

“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma”

Helmy Eltoukhy, Co-Founder and Co-CEO · Q3 2026 results release, November 5, 2026

“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests”

AmirAli Talasaz, Co-Founder and Co-CEO · Q3 2026 results release, November 5, 2026

“We remain confident in achieving company-wide free cash flow breakeven by the end of 2027.”

Michael Bell, CFO · Q3 2026 earnings call, November 5, 2026

“Every commercial product runs on the platform”

Helmy Eltoukhy, Co-Founder and Co-CEO · Q3 2026 earnings call, November 5, 2026

Where a supplier can help

Lab automation and sequencing efficiency
Tied to the Shield cost per test priority: automation, robotics and workflow tools for the new Palo Alto lab on the path to $200 per test.
Security and patient data protection
Tied to the cybersecurity incident: identity, portal security and monitoring solutions for physician ordering and patient records.
Revenue cycle and payer contracting
Tied to the reimbursement challenge: billing, claims and contracting tools as commercial coverage and ADLT status expand.
Direct-to-consumer marketing
Tied to the Shield scale-up priority: media, patient engagement and primary care outreach as DTC spending increases into 2027.
AI and data infrastructure
Tied to the data and AI platform priority: compute, data management and clinical AI tooling for the InfinityAI engine and physician decision support.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Guardant Health?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Guardant Health

What does Guardant Health do?

Guardant Health sells blood and tissue tests for cancer screening (Shield), recurrence monitoring (Reveal) and therapy selection (Guardant360), plus tests, data and companion diagnostic services for biopharma companies.

What is Guardant Health's revenue?

FY2025 revenue was $982.0 million, up 33%. Q3 2026 revenue was $361.0 million, and 2026 guidance is $1.36-$1.37 billion.

How many employees does Guardant Health have?

Guardant had 2,506 employees at December 31, 2025, about 2,278 in the U.S.

What is Guardant Health's strategy?

Guardant aims to lead in therapy selection, MRD and early cancer screening on its Smart Platform, scaling Shield, cutting test costs and reaching company-wide free cash flow breakeven by the end of 2027.

Who leads Guardant Health?

Co-founders Helmy Eltoukhy and AmirAli Talasaz are Co-CEOs; Michael Bell is CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)